Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification

Keyphrases

• Patient-derived Xenograft 100%
• Precision Medicine 100%
• Lung Adenocarcinoma 100%
• HER2 Amplification 100%
• MET Amplification 100%
• Patient Tumor 28%
• Array Comparative Genomic Hybridization (aCGH) 28%
• Lung Cancer Patients 28%
• HER2 Overexpression 28%
• Lung Cancer 14%
• Histopathological Features 14%
• Genetic Features 14%
• Targeted Therapy 14%
• Cancer Patients 14%
• Genome Sequence Analysis 14%
• Human Epidermal Growth Factor Receptor 2 (HER2) 14%
• Cancer Treatment 14%
• Cell Growth 14%
• One Sample 14%
• Oncogene mutation 14%
• Patient-derived Tumor Xenograft 14%
• Surgical Specimen 14%
• Copy number Analysis 14%
• Targeted Agents 14%
• Receptor Tyrosine Kinase 14%
• Pathway Alteration 14%
• Genomic Profiling 14%
• Driver mutations 14%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 14%
• Metagenomic Next-generation Sequencing (mNGS) 14%
• Tyrosine Kinase Inhibitor Treatment 14%
• Crizotinib 14%
• Cancer Panel 14%
• Tumor Sphere Formation 14%
• Personalized Targeted Therapy 14%
• Drug Screening Platform 14%
• MET Inhibitor 14%
• Preclinical Drug Screening 14%
• MET Overexpression 14%
• Treat Cancer 14%
• Tumor-derived 14%
• Epidermal Growth Factor Receptor Inhibitors (EGFRI) 14%
• Established Patient 14%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Targeted Therapy 100%
• Genetics 50%
• Next Generation Sequencing 50%
• Array Comparative Genomic Hybridization 50%
• Oncogene 50%
• Copy Number Analysis 50%
• Cell Growth 50%
• Carcinogenesis 50%
• Tyrosine Kinase Inhibitor 50%
• Receptor Tyrosine Kinase 50%
• Drug Screening 50%
• Genomics 50%
• Crizotinib 50%

Medicine and Dentistry

• Personalized Medicine 100%
• Lung Adenocarcinoma 100%
• Lung Cancer 60%
• Malignant Neoplasm 40%
• Targeted Therapy 40%
• Xenograft 40%
• Tumor 40%
• Genetics 40%
• Neoplasm 20%
• In Vitro 20%
• Carcinogenesis 20%
• Cancer Therapy 20%
• Epidermal Growth Factor Receptor 20%
• Cell Growth 20%
• Protein Tyrosine Kinase 20%
• Oncogene 20%
• Next Generation Sequencing 20%
• Tumor Xenograft 20%
• Drug Screening 20%
• Tyrosine-Kinase Inhibitor 20%
• EGFR Inhibitors 20%
• Array Comparative Genomic Hybridization 20%